A Comparison of the Cost-Saving Impact of Biosimilar Switching Policies across Canadian Provinces: A Case-Study for a Ranibizumab Biosimilar
Author(s)
Keady S1, Goyert-Stephens N2, Xin Q3, Morris L4, Thomas M4, Foxon G5
1Biogen International HQ, Switzerland, London, LON, UK, 2Biogen Canada, Toronto, ON, Canada, 3Biogen International HQ, Switzerland, Baar, ZG, Switzerland, 4Remap Consulting UK Ltd, Alderley Edge, CHE, UK, 5Remap Consulting UK Ltd, Rainow, CHE, UK
Presentation Documents
OBJECTIVES:
This examined the impact of differing ophthalmology biosimilar switching policies on cost-savings for Canadian payors. The anticipated budget impact of a ranibizumab biosimilar was estimated across ten provincial drug plans. Resulting analysis identified possible opportunities for increased drug plan cost-savings associated with adopting proactive biosimilar switching policies.METHODS:
Provincial biosimilar switching policies were identified. Two scenarios were modelled: a market with ranibizumab biosimilars, and a market without. Uptake was based on historical data of etanercept and adalimumab biosimilar uptake in Canada. The model used growth rates of ranibizumab of 5%, 3%, 2% and 1.5% for years 2022-25. Scenario analysis was performed to forecast budget impact resulting from all provinces implementing proactive switching policies. For proactive and non-proactive switching policies, at month 36 market share was capped at 96.4% and 31.4% respectively. Budget impact over a three-year period was calculated and sensitivity analyses conducted. Cost-savings were compared between provinces and switching policies.RESULTS:
British Columbia, Alberta, Saskatchewan, Quebec, New Brunswick and Nova Scotia were identified as having proactive switching policies. Prince Edward Island, Ontario, Manitoba and Newfoundland & Labrador had optional, tiered or de novo only switching policies. Over a three-year horizon, total savings estimated for all identified proactive switching provinces could be CAD$48,719,418, compared to CAD$24,352,109 for non-proactive provinces. With a proactive switching policy scenario, savings of CAD$93,873,816 were projected for non-proactive provinces. If a national proactive switch policy was adopted, possible overall savings of CAD$142,593,234 were projected. Comparatively, with a national non-proactive switching scenario, overall savings of only CAD$36,890,564 could be gained.CONCLUSIONS:
The anticipated Canadian launches of ophthalmologic biosimilars are poised to provide significant savings to the healthcare system. Adoption of more proactive switching policies could dramatically increase overall savings, which are essential to bolster provincial drug plans sustainability and facilitate continued reimbursement of innovative therapeutic options for Canadian patients.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
EE426
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Budget Impact Analysis, Public Spending & National Health Expenditures, Reimbursement & Access Policy
Disease
Biologics & Biosimilars